• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Nausea Medicine Market Share

    ID: MRFR/Pharma/3105-CR
    104 Pages
    Rahul Gotadki
    February 2021

    Global Nausea Medicine Market Research Report Information By Type (Antagonists, Antihistamines, Cannabinoids and Others), By Mode of Administration (Intravenous, Oral and Transdermal), Indication (Oncology, Gastroesophageal Reflux Disease (GERD), Motion Sickness and Seasickness and Others), Distribution Channel (Hospitals Pharmacy/ Retail Pharmacy and Online), Region (Americas, Europe, Asia-Pac...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Nausea Medicine Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Share

    Nausea Medicine Market Share Analysis

    In the competitive landscape of the Nausea Medicine Market, market share positioning strategies play a pivotal role in determining the success of pharmaceutical companies. These strategies revolve around establishing a strong presence in the market and gaining a competitive edge over rivals. One key approach is differentiation, where companies distinguish their products from competitors through unique features, such as extended-release formulations or novel delivery methods. By offering something distinct, companies can attract a segment of the market seeking specific benefits or experiences, thereby capturing market share.

    Moreover, pricing strategies are critical in market share positioning. Some companies opt for penetration pricing, setting lower prices to quickly gain market share and establish their brand. This approach can be particularly effective in markets where price sensitivity is high or where there are generic alternatives. Conversely, premium pricing can be employed by positioning the product as superior in quality or efficacy, targeting segments willing to pay a premium for perceived value. Balancing price with perceived value is essential for companies to effectively capture and retain market share.

    Distribution channels also play a crucial role in market share positioning. Companies may choose to partner with various distribution channels, such as pharmacies, hospitals, or online platforms, to ensure widespread availability and accessibility of their products. By reaching customers through multiple channels, companies can increase their market penetration and capture a larger share of the market. Additionally, strategic alliances with healthcare providers or institutions can further enhance distribution networks and strengthen market positioning.

    Innovation is another key driver of market share positioning in the Nausea Medicine Market. Companies that invest in research and development to continuously improve their products or develop new formulations can gain a competitive advantage. Whether it's introducing a new active ingredient with enhanced efficacy or developing user-friendly packaging, innovation can differentiate a company's offering and attract consumers seeking advanced solutions. Furthermore, securing patents or intellectual property rights for innovative products can create barriers to entry for competitors, solidifying a company's market position.

    Marketing and branding strategies also play a crucial role in market share positioning. Effective branding can create strong emotional connections with consumers and differentiate a product from competitors. Companies may leverage various marketing channels, such as advertising, social media, and influencer partnerships, to raise awareness and promote their products. Additionally, investing in educational initiatives to inform consumers about the causes and treatment of nausea can position a company as a trusted authority in the market, enhancing its credibility and market share.

    Furthermore, understanding and catering to the needs of different customer segments is essential for effective market share positioning. By conducting market research and analyzing consumer preferences, companies can tailor their products and marketing strategies to specific demographics or medical conditions. For example, developing pediatric-friendly formulations or targeting pregnant women with morning sickness can help companies capture niche segments of the market and increase their overall market share.

    Market Summary

    The Global Nausea Medicine Market is projected to grow from 3.66 USD Billion in 2024 to 7.69 USD Billion by 2035.

    Key Market Trends & Highlights

    Nausea Medicine Key Trends and Highlights

    • The market is expected to expand at a compound annual growth rate (CAGR) of 6.98% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 7.69 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 3.66 USD Billion, reflecting a solid foundation for future expansion.
    • Growing adoption of innovative treatment options due to increasing prevalence of nausea-related conditions is a major market driver.

    Market Size & Forecast

    2024 Market Size 3.66 (USD Billion)
    2035 Market Size 7.69 (USD Billion)
    CAGR (2025-2035) 6.98%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Novartis AG (Switzerland), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Pfizer Inc. (US), Sanofi S.A. (France), Mylan NV (US), AstraZeneca (UK), Cipla Inc. (India)

    Market Trends

    The increasing prevalence of gastrointestinal disorders and the rising awareness of nausea management options appear to drive growth in the global nausea medicine market.

    U.S. National Library of Medicine

    Nausea Medicine Market Market Drivers

    Market Growth Projections

    The Global Nausea Medicine Market Industry is projected to experience robust growth, with a compound annual growth rate (CAGR) of 6.98% anticipated from 2025 to 2035. This growth trajectory reflects the increasing demand for effective nausea treatments driven by various factors, including the rising incidence of nausea disorders and advancements in pharmaceutical research. The market is expected to reach a valuation of 7.69 USD Billion by 2035, indicating a strong upward trend. This growth presents opportunities for stakeholders to innovate and expand their product offerings in response to the evolving needs of consumers.

    Growing Geriatric Population

    The aging population is a significant driver of the Global Nausea Medicine Market Industry. Older adults are more susceptible to nausea due to various health conditions and medications they may be taking. As the global geriatric population continues to rise, the demand for effective nausea treatments is expected to increase correspondingly. This demographic shift is prompting pharmaceutical companies to focus on developing tailored nausea medications that cater to the unique needs of older patients. Consequently, this trend is likely to bolster market growth as the industry adapts to meet the needs of this expanding population.

    Increased Awareness and Education

    There is a growing emphasis on patient education and awareness regarding nausea disorders, which is positively impacting the Global Nausea Medicine Market Industry. Healthcare providers are increasingly informing patients about the causes and treatments of nausea, leading to higher treatment-seeking behavior. Campaigns aimed at educating the public about nausea management are becoming more prevalent, fostering a better understanding of available therapies. This increased awareness is likely to contribute to market growth, as more individuals seek effective solutions for their nausea-related issues.

    Rising Incidence of Nausea Disorders

    The Global Nausea Medicine Market Industry is experiencing growth due to the increasing prevalence of nausea-related disorders. Conditions such as motion sickness, chemotherapy-induced nausea, and pregnancy-related nausea are becoming more common. For instance, the World Health Organization indicates that millions of people worldwide suffer from these conditions annually. This rising incidence necessitates effective treatment options, thereby driving demand for nausea medications. As the market evolves, it is projected to reach 3.66 USD Billion in 2024, reflecting a growing awareness and need for effective nausea management solutions.

    Expansion of Over-the-Counter Options

    The Global Nausea Medicine Market Industry is witnessing a notable expansion in over-the-counter (OTC) medication options. The availability of non-prescription nausea relief products is making treatment more accessible to consumers. This trend is particularly relevant for mild nausea cases, where individuals prefer to self-manage their symptoms. The rise of e-commerce platforms has further facilitated access to these OTC products, allowing consumers to purchase them conveniently. As a result, the market is likely to experience increased sales and a broader consumer base, contributing to its overall growth.

    Advancements in Pharmaceutical Research

    Innovations in pharmaceutical research are propelling the Global Nausea Medicine Market Industry forward. The development of new antiemetic drugs and formulations is enhancing treatment efficacy and patient compliance. For example, advancements in targeted therapies and personalized medicine are leading to more effective nausea management strategies. These innovations not only improve patient outcomes but also expand the market by introducing novel products. As a result, the market is expected to grow significantly, with projections indicating a value of 7.69 USD Billion by 2035, highlighting the potential for continued advancements in this field.

    Market Segment Insights

    Nausea Medicine Type Insights

    The nausea medicine market, on the basis of type, has been segmented into antagonists, cannabinoids, antihistamines, and others. 

    Nausea Medicine Mode of Administation Insights

    The nausea medicine market, based on the mode of administration, is divided into oral, intravenous, and others. The nausea medicine market, based on indication, is divided into oncology, gastroesophageal reflux disease (GERD), motion sickness, and others. The nausea medicine market, based on distribution channel, is divided into hospital/retail pharmacies and online.

    By indication, the oncology segment held the largest share of 39.84% in 2019 owing to an increasing number of patients experiencing nausea associated with chemotherapeutic drug use.

    Get more detailed insights about Nausea Medicine Market Research Report - Global Forecast till 2032

    Regional Insights

    Key Companies in the Nausea Medicine Market market include

    Industry Developments

    Future Outlook

    Nausea Medicine Market Future Outlook

    The Global Nausea Medicine Market is projected to grow at a 6.98% CAGR from 2024 to 2035, driven by increasing healthcare access, rising awareness of treatment options, and advancements in drug formulations.

    New opportunities lie in:

    • Develop personalized nausea treatments leveraging genetic insights.
    • Expand telehealth services for nausea management in remote areas.
    • Invest in research for novel antiemetic compounds targeting specific patient demographics.

    By 2035, the market is expected to exhibit robust growth, reflecting evolving consumer needs and innovative therapeutic solutions.

    Market Segmentation

    Type Outlook

    • Antagonists
    • Antihistamines
    • Cannabinoids
    • Others

    Mode of Administration Outlook

    • Intravenous
    • Oral
    • Transdermal

    Nausea Medicine Region Outlook

    Americas
    • North AmericaUS Canada
    • US
    • Canada

     Nausea Medicine Type Outlook

    • Antagonists
    • Antihistamines
    • Cannabinoids
    • Others

     Nausea Medicine Indication Outlook

    • Oncology
    • Gastroesophageal Reflux Disease (GERD)
    • Motion Sickness And Seasickness
    • Others

    Nausea Medicine Distribution Channel Outlook

    • Hospitals Pharmacy/ Retail Pharmacy
    • Online

    Nausea Medicine Mode of Administration Outlook

    • Intravenous
    • Oral
    • Transdermal

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 3.42 (USD Billion)
    Market Size 2024 3.66 (USD Billion)
    Market Size 2032 6.24 (USD Billion)
    Compound Annual Growth Rate (CAGR) 7.2 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific and Rest of the World (RoW)
      Key Vendors   Novartis AG (Switzerland), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Pfizer Inc. (US), Sanofi S.A. (France), Mylan NV (US), AstraZeneca (UK), Cipla Inc. (India)
      Key Market Opportunities   Drug manufacturing companies and small companies
      Key Market Drivers ·  Gastrointestinal diseases ·  Increasing geriatric population ·  Sedentary lifestyle ·  Unhealthy diet

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    What is Global Nausea Medicine Market?

    The Global Nausea Medicine Market include By Type (Antagonists, Antihistamines, Cannabinoids and Others), By Mode of Administration (Intravenous, Oral and Transdermal), Indication (Oncology, Gastroesophageal Reflux Disease (GERD), Motion Sickness and Seasickness and Others), Distribution Channel (Hospitals Pharmacy/ Retail Pharmacy and Online), Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2032.

    Which is the largest segment in the global Nausea Medicine Market?

    The Oncology is largest segment on the basis of Indication in the global Nausea Medicine Market.

    What are the major tailwinds pushing the growth of the Nausea Medicine Market?

    Increasing geriatric population and Sedentary lifestyle are the major tailwinds pushing the growth of the Nausea Medicine Market.

    Which region holds the largest share in the Nausea Medicine Market?

    The Americas holds the largest share in the Nausea Medicine Market.

    1. Executive Summary
      1. OVERVIEW 14
        1. MARKET SYPNOSIS 14
    2. Market Introduction
      1. DEFINITION 15
      2. Scope of the Study 15
      3. RESEARCH OBJECTIVE 15
      4. MARKET STRUCTURE 15
      5. ASSUMPTIONS & LIMITATIONS 16
    3. Research Methodology
      1. DATA MINING 17
      2. SECONDARY RESEARCH 18
      3. PRIMARY RESEARCH 18
      4. BREAKDOWN OF PRIMARY RESPONDENTS 19
      5. FORECASTING TECHNIQUES 20
      6. Research Methodology FOR MARKET SIZE ESTIMATION 21
        1. Bottom-up Approach 22
        2. TOP-DOWN APPROACH 22
      7. DATA TRIANGULATION 23
      8. VALIDATION 23
    4. MARKET DYNAMICS
      1. OVERVIEW 24
      2. DRIVERS 25
        1. GROWING CASES OF CANCER 25
        2. RISE IN GASTROINTESTINAL DISEASES 25
        3. INCREASING GERIATRIC POPULATION, SEDENTARY LIFESTYLE, AND UNHEALTHY DIET 25
      3. RESTRAINTS 26
        1. HIGH PREFERENCE FOR HOME REMEDIES 26
      4. OPPORTUNITIES 27
        1. COLLABORATIONS BETWEEN LARGE DRUG MANUFACTURING COMPANY AND SMALL COMPANIES 27
    5. MARKET FACTOR ANALYSIS
      1. VALUE CHAIN ANALYSIS 28
        1. R&D AND DESIGNING 29
        2. MANUFACTURING 29
        3. DISTRIBUTION & SALES 29
        4. POST-SALES SERVICES 29
      2. PORTER’S FIVE FORCES MODEL 30
        1. BARGAINING POWER OF SUPPLIERS 31
        2. BARGAINING POWER OF BUYERS 31
        3. THREAT OF NEW ENTRANTS 31
        4. THREAT OF SUBSTITUTES 31
        5. INTENSITY OF RIVALRY 31
    6. GLOBAL NAUSEA MEDICINE MARKET, BY TYPE
      1. OVERVIEW 32
      2. ANTAGONISTS 33
      3. ANTIHISTAMINES 33
      4. CANNABINOIDS 34
      5. OTHERS 34
    7. GLOBAL NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION
      1. OVERVIEW 35
      2. INTRAVENOUS 36
      3. ORAL 36
      4. TRANSDERMAL 37
    8. GLOBAL NAUSEA MEDICINE MARKET, BY INDICATION
      1. OVERVIEW 38
      2. ONCOLOGY 39
      3. GASTROESOPHAGEAL REFLUX DISEASE (GERD) 39
      4. MOTION SICKNESS AND SEASICKNESS 40
      5. OTHERS 40
    9. GLOBAL NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL
      1. OVERVIEW 41
      2. HOSPITALS PHARMACY/ RETAIL PHARMACY 42
      3. ONLINE 42
    10. GLOBAL NAUSEA MEDICINE MARKET, BY REGION
      1. OVERVIEW 43
      2. AMERICAS 44
        1. NORTH AMERICA 46
        2. SOUTH AMERICA 51
      3. EUROPE 53
        1. WESTERN EUROPE 55
        2. EASTERN EUROPE 65
      4. ASIA-PACIFIC 67
        1. CHINA 69
        2. JAPAN 70
        3. INDIA 72
        4. AUSTRALIA 73
        5. SOUTH KOREA 74
        6. REST OF ASIA-PACIFIC 76
      5. MIDDLE EAST & AFRICA 78
        1. MIDDLE EAST 80
        2. AFRICA 81
    11. Competitive Landscape
      1. OVERVIEW 83
      2. MAJOR PLAYERS IN THE GLOBAL NAUSEA MEDICINE MARKET 83
      3. COMPETITIVE BENCHMARKING 84
      4. COMPETITOR DASHBOARD 85
      5. KEY DEVELOPMENTS & GROWTH STRATEGIES 85
        1. ACQUISITIONS 85
    12. COMPANY PROFILES
      1. SANOFI S.A. 86
        1. COMPANY OVERVIEW 86
        2. FINANCIAL OVERVIEW 86
        3. PRODUCTS/SERVICES OFFERED 87
        4. KEY DEVELOPMENTS 87
        5. SWOT ANALYSIS 87
        6. KEY STRATEGIES 87
      2. NOVARTIS AG 88
        1. COMPANY OVERVIEW 88
        2. FINANCIAL OVERVIEW 88
        3. PRODUCTS/SERVICES OFFERED 89
        4. KEY DEVELOPMENTS 89
        5. SWOT ANALYSIS 89
        6. KEY STRATEGIES 89
      3. MERCK & CO., INC. 90
        1. COMPANY OVERVIEW 90
        2. FINANCIAL OVERVIEW 90
        3. PRODUCTS/SERVICES OFFERED 91
        4. KEY DEVELOPMENTS 91
        5. SWOT ANALYSIS 91
        6. KEY STRATEGIES 91
      4. GLAXOSMITHKLINE PLC 92
        1. COMPANY OVERVIEW 92
        2. FINANCIAL OVERVIEW 92
        3. PRODUCTS/SERVICES OFFERED 93
        4. KEY DEVELOPMENTS 93
        5. SWOT ANALYSIS 93
        6. KEY STRATEGIES 94
      5. MYLAN NV 95
        1. COMPANY OVERVIEW 95
        2. FINANCIAL OVERVIEW 95
        3. PRODUCTS/SERVICES OFFERED 96
        4. KEY DEVELOPMENTS 96
        5. SWOT ANALYSIS 96
        6. KEY STRATEGIES 96
      6. PFIZER INC. 97
        1. COMPANY OVERVIEW 97
        2. FINANCIAL OVERVIEW 97
        3. PRODUCTS/SERVICES OFFERED 98
        4. KEY DEVELOPMENTS 98
        5. SWOT ANALYSIS 98
        6. KEY STRATEGIES 98
      7. F. HOFFMANN-LA ROCHE LTD 99
        1. COMPANY OVERVIEW 99
        2. FINANCIAL OVERVIEW 99
        3. PRODUCTS/SERVICES OFFERED 100
        4. KEY DEVELOPMENTS 100
        5. SWOT ANALYSIS 100
        6. KEY STRATEGIES 100
      8. ASTRAZENECA 101
        1. COMPANY OVERVIEW 101
        2. FINANCIAL OVERVIEW 101
        3. PRODUCTS/SERVICES OFFERED 102
        4. KEY DEVELOPMENTS 102
        5. SWOT ANALYSIS 102
        6. KEY STRATEGIES 102
      9. CIPLA INC. 103
        1. COMPANY OVERVIEW 103
        2. FINANCIAL OVERVIEW 103
        3. PRODUCTS/SERVICES OFFERED 104
        4. KEY DEVELOPMENTS 104
        5. SWOT ANALYSIS 104
        6. KEY STRATEGIES 104
    13. APPENDIX
      1. REFERENCES 105
      2. RELATED REPORTS 105
    14. List of Tables and Figures
      1. 14 LIST OF TABLES
      2. TABLE 1 LIST OF ASSUMPTIONS 16
      3. TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19
      4. TABLE 3 GLOBAL NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 32
      5. TABLE 4 GLOBAL NAUSEA MEDICINE MARKET, FOR ANTAGONISTS, BY REGION, 2023–2030 (USD MILLION) 33
      6. TABLE 5 GLOBAL NAUSEA MEDICINE MARKET, FOR ANTIHISTAMINES, BY REGION, 2023–2030 (USD MILLION) 33
      7. TABLE 6 GLOBAL NAUSEA MEDICINE MARKET, FOR CANNABINOIDS, BY REGION, 2023–2030 (USD MILLION) 34
      8. TABLE 7 GLOBAL NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 35
      9. TABLE 8 GLOBAL NAUSEA MEDICINE MARKET, FOR INTRAVENOUS, BY REGION 2023–2030 (USD MILLION) 36
      10. TABLE 9 GLOBAL NAUSEA MEDICINE MARKET, FOR ORAL, BY REGION 2023–2030 (USD MILLION) 36
      11. TABLE 10 GLOBAL NAUSEA MEDICINE MARKET, FOR TRANSDERMAL, BY REGION 2023–2030 (USD MILLION) 37
      12. TABLE 11 GLOBAL NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 38
      13. TABLE 12 GLOBAL NAUSEA MEDICINE MARKET, FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 39
      14. TABLE 13 GLOBAL NAUSEA MEDICINE MARKET, FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD), BY REGION, 2023–2030 (USD MILLION) 39
      15. TABLE 14 GLOBAL NAUSEA MEDICINE MARKET, FOR MOTION SICKNESS AND SEASICKNESS, BY REGION, 2023–2030 (USD MILLION) 40
      16. TABLE 15 GLOBAL NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 41
      17. TABLE 16 GLOBAL NAUSEA MEDICINE MARKET, FOR HOSPITALS PHARMACY/ RETAIL PHARMACY, BY REGION, 2023–2030 (USD MILLION) 42
      18. TABLE 17 GLOBAL NAUSEA MEDICINE MARKET, FOR ONLINE, BY REGION,2023–2030 (USD MILLION) 42
      19. TABLE 18 GLOBAL NAUSEA MEDICINE MARKET, BY REGION 2023–2030 (USD MILLION) 43
      20. TABLE 19 AMERICAS NAUSEA MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION) 44
      21. TABLE 20 AMERICAS NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 45
      22. TABLE 21 AMERICAS NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 45
      23. TABLE 22 AMERICAS NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 45
      24. TABLE 23 AMERICAS NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 46
      25. TABLE 24 NORTH AMERICA NAUSEA MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION) 46
      26. TABLE 25 NORTH AMERICA NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 47
      27. TABLE 26 NORTH AMERICA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 47
      28. TABLE 27 NORTH AMERICA NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 47
      29. TABLE 28 NORTH AMERICA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 48
      30. TABLE 29 US NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 48
      31. TABLE 30 US NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 48
      32. TABLE 31 US NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 49
      33. TABLE 32 US NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 49
      34. TABLE 33 CANADA NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 49
      35. TABLE 34 CANADA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 50
      36. TABLE 35 CANADA NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 50
      37. TABLE 36 CANADA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 50
      38. TABLE 37 SOUTH AMERICA NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 51
      39. TABLE 38 SOUTH AMERICA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 51
      40. TABLE 39 SOUTH AMERICA NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 51
      41. TABLE 40 SOUTH AMERICA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 52
      42. TABLE 41 EUROPE NAUSEA MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION) 53
      43. TABLE 42 EUROPE NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 54
      44. TABLE 43 EUROPE NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 54
      45. TABLE 44 EUROPE NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 54
      46. TABLE 45 EUROPE NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 55
      47. TABLE 46 WESTERN EUROPE NAUSEA MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION) 55
      48. TABLE 47 WESTERN EUROPE NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 56
      49. TABLE 48 WESTERN EUROPE NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 56
      50. TABLE 49 WESTERN EUROPE NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 56
      51. TABLE 50 WESTERN EUROPE NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 57
      52. TABLE 51 GERMANY NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 57
      53. TABLE 52 GERMANY NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 57
      54. TABLE 53 GERMANY NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 58
      55. TABLE 54 GERMANY NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 58
      56. TABLE 55 FRANCE NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 58
      57. TABLE 56 FRANCE NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 59
      58. TABLE 57 FRANCE NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 59
      59. TABLE 58 FRANCE NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 59
      60. TABLE 59 UK NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 60
      61. TABLE 60 UK NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 60
      62. TABLE 61 UK NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 60
      63. TABLE 62 UK NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 61
      64. TABLE 63 ITALY NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 61
      65. TABLE 64 ITALY NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 61
      66. TABLE 65 ITALY NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 62
      67. TABLE 66 ITALY NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 62
      68. TABLE 67 SPAIN NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 62
      69. TABLE 68 SPAIN NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 63
      70. TABLE 69 SPAIN NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 63
      71. TABLE 70 SPAIN NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 63
      72. TABLE 71 REST OF WESTERN EUROPE NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 64
      73. TABLE 72 REST OF WESTERN EUROPE NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 64
      74. TABLE 73 REST OF WESTERN EUROPE NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 64
      75. TABLE 74 REST OF WESTERN EUROPE NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 65
      76. TABLE 75 EASTERN EUROPE NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 65
      77. TABLE 76 EASTERN EUROPE NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 65
      78. TABLE 77 EASTERN EUROPE NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 66
      79. TABLE 78 EASTERN EUROPE NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 66
      80. TABLE 79 ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 67
      81. TABLE 80 ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 68
      82. TABLE 81 ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 68
      83. TABLE 82 ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 68
      84. TABLE 83 ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 69
      85. TABLE 84 CHINA NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 69
      86. TABLE 85 CHINA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 69
      87. TABLE 86 CHINA NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 70
      88. TABLE 87 CHINA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 70
      89. TABLE 88 JAPAN NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 70
      90. TABLE 89 JAPAN NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 71
      91. TABLE 90 JAPAN NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 71
      92. TABLE 91 JAPAN NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 71
      93. TABLE 92 INDIA NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 72
      94. TABLE 93 INDIA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 72
      95. TABLE 94 INDIA NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 72
      96. TABLE 95 INDIA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 73
      97. TABLE 96 AUSTRALIA NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 73
      98. TABLE 97 AUSTRALIA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 73
      99. TABLE 98 AUSTRALIA NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 74
      100. TABLE 99 AUSTRALIA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 74
      101. TABLE 100 SOUTH KOREA NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 74
      102. TABLE 101 SOUTH KOREA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 75
      103. TABLE 102 SOUTH KOREA NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 75
      104. TABLE 103 SOUTH KOREA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 75
      105. TABLE 104 REST OF ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 76
      106. TABLE 105 REST OF ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 76
      107. TABLE 106 REST OF ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 76
      108. TABLE 107 REST OF ASIA-PACIFIC NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 77
      109. TABLE 108 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET, BY REGION 2023–2030 (USD MILLION) 78
      110. TABLE 109 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 79
      111. TABLE 110 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 79
      112. TABLE 111 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 79
      113. TABLE 112 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 80
      114. TABLE 113 MIDDLE EAST NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 80
      115. TABLE 114 MIDDLE EAST NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 80
      116. TABLE 115 MIDDLE EAST NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 81
      117. TABLE 116 MIDDLE EAST NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 81
      118. TABLE 117 AFRICA NAUSEA MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION) 81
      119. TABLE 118 AFRICA NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023–2030 (USD MILLION) 82
      120. TABLE 119 AFRICA NAUSEA MEDICINE MARKET, BY INDICATION, 2023–2030 (USD MILLION) 82
      121. TABLE 120 AFRICA NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023–2030 (USD MILLION) 82
      122. TABLE 121 MAJOR PLAYERS IN THE GLOBAL NAUSEA MEDICINE MARKET 83
      123. TABLE 122 ACQUISITIONS 85
      124. TABLE 123 SANOFI S.A.: PRODUCTS/SERVICES OFFERED 87
      125. TABLE 124 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 89
      126. TABLE 125 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED 91
      127. TABLE 126 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 93
      128. TABLE 127 GLAXOSMITHKLINE PLC: KEY DEVELOPMENTS 93
      129. TABLE 128 MYLAN NV: PRODUCTS/SERVICES OFFERED 96
      130. TABLE 129 PFIZER INC.: PRODUCTS/SERVICES OFFERED 98
      131. TABLE 130 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 100
      132. TABLE 131 ASTRAZENECA: PRODUCTS/SERVICES OFFERED 102
      133. TABLE 132 CIPLA INC.: PRODUCTS/SERVICES OFFERED 104 15 LIST OF FIGURES
      134. FIGURE 1 GLOBAL NAUSEA MEDICINE MARKET: STRUCTURE 15
      135. FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 21
      136. FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL NAUSEA MEDICINE MARKET 24
      137. FIGURE 4 DRIVER IMPACT ANALYSIS 26
      138. FIGURE 5 RESTRAINT IMPACT ANALYSIS 26
      139. FIGURE 6 VALUE CHAIN: GLOBAL NAUSEA MEDICINE MARKET 28
      140. FIGURE 7 PORTER’S FIVE FORCES ANALYSIS: GLOBAL NAUSEA MEDICINE MARKET 30
      141. FIGURE 8 GLOBAL NAUSEA MEDICINE MARKET, BY TYPE, 2023 & 2030 (USD MILLION) 32
      142. FIGURE 9 GLOBAL NAUSEA MEDICINE MARKET, BY MODE OF ADMINISTRATION, 2023 & 2030 (USD MILLION) 35
      143. FIGURE 10 GLOBAL NAUSEA MEDICINE MARKET, BY INDICATION, 2023 & 2030 (USD MILLION) 38
      144. FIGURE 11 GLOBAL NAUSEA MEDICINE MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2030 (USD MILLION) 41
      145. FIGURE 12 GLOBAL NAUSEA MEDICINE MARKET SHARE, BY REGION 2023 (%) 43
      146. FIGURE 13 AMERICAS NAUSEA MEDICINE MARKET SHARE, BY REGION, 2023 (%) 44
      147. FIGURE 14 NORTH AMERICA NAUSEA MEDICINE MARKET SHARE, BY REGION, 2023 (%) 46
      148. FIGURE 15 EUROPE NAUSEA MEDICINE MARKET SHARE, BY COUNTRY/REGION, 2023 (%) 53
      149. FIGURE 16 WESTERN EUROPE NAUSEA MEDICINE MARKET SHARE, BY COUNTRY/REGION, 2023 (%) 55
      150. FIGURE 17 ASIA-PACIFIC NAUSEA MEDICINE MARKET SHARE, BY COUNTRY/REGION, 2023 (%) 67
      151. FIGURE 18 MIDDLE EAST & AFRICA NAUSEA MEDICINE MARKET SHARE, BY COUNTRY/REGION, 2023 (%) 78
      152. FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS 84
      153. FIGURE 20 COMPETITOR DASHBOARD: GLOBAL NAUSEA MEDICINE MARKET 85
      154. FIGURE 21 SANOFI S.A.: FINANCIAL OVERVIEW SNAPSHOT 86
      155. FIGURE 22 SANOFI S.A.: SWOT ANALYSIS 87
      156. FIGURE 23 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 88
      157. FIGURE 24 NOVARTIS AG: SWOT ANALYSIS 89
      158. FIGURE 25 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 90
      159. FIGURE 26 MERCK & CO., INC.: SWOT ANALYSIS 91
      160. FIGURE 27 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 92
      161. FIGURE 28 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 93
      162. FIGURE 29 MYLAN NV: FINANCIAL OVERVIEW SNAPSHOT 95
      163. FIGURE 30 MYLAN NV: SWOT ANALYSIS 96
      164. FIGURE 31 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 97
      165. FIGURE 32 PFIZER INC.: SWOT ANALYSIS 98
      166. FIGURE 33 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 99
      167. FIGURE 34 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 100
      168. FIGURE 35 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 101
      169. FIGURE 36 ASTRAZENECA: SWOT ANALYSIS 102
      170. FIGURE 37 CIPLA INC: FINANCIAL OVERVIEW SNAPSHOT 103
      171. FIGURE 38 CIPLA INC.: SWOT ANALYSIS 104

    Nausea Medicine Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials